Hidden Heart Risk Beyond Bad Cholesterol Revealed in New Study

For decades, the medical establishment has focused on lowering LDL cholesterol as the primary strategy for preventing heart attacks. Millions of patients worldwide take statins and other cholesterol-lowering medications, faithfully monitoring their lipid panels. Yet a persistent mystery has confounded cardiologists: why do some people still suffer heart attacks even after bringing their bad cholesterol down to recommended levels?

A groundbreaking study published in the European Heart Journal by researchers at Chalmers University of Technology in Sweden may finally provide an answer. The findings reveal that two types of fat-carrying particles in the blood, previously overshadowed by the focus on LDL, may be driving cardiovascular damage through entirely different biological mechanisms, including inflammation and blood vessel remodeling.

The Cholesterol Paradox

According to the World Health Organization, cardiovascular diseases kill nearly 17.9 million people worldwide each year, with heart attacks and strokes accounting for more than 80 percent of those deaths. The standard approach to prevention has been clear: reduce LDL cholesterol, and you reduce your risk of a heart attack.

However, bringing LDL cholesterol into the recommended range does not eliminate the danger entirely. Some patients continue to develop coronary heart disease despite successful cholesterol-lowering treatment. This phenomenon, known in cardiology circles as residual cardiovascular risk, has been a significant blind spot in preventive medicine.

For this study, we wanted to understand what happens beyond the accumulation of cholesterol in artery walls, said Jakub Morze, lead author and postdoctoral fellow at Chalmers University of Technology. Whether different fat-carrying particles can damage the blood vessels differently and why the remaining risk of heart disease still occurs.

Three Particles, Three Different Threats

Cholesterol and other fats cannot travel through the bloodstream on their own. They are transported by specialized particles called lipoproteins. Three major classes of these particles contain a surface protein called apolipoprotein B, or apoB. All three can deposit cholesterol inside artery walls, but the Chalmers research reveals they do not all cause damage in the same way.

• LDL (Low-Density Lipoprotein): The most abundant cholesterol carrier in the blood. Its associated proteins were primarily connected to cholesterol accumulation in artery walls, the classic mechanism that statins target.
• TRL (Triglyceride-Rich Lipoproteins): These particles transport cholesterol along with triglycerides, which the body uses as an energy source. As triglycerides are removed, the remaining fragments can deposit cholesterol in arteries. The study found TRL particles carry proteins that attract immune cells, promoting inflammation and structural changes in blood vessel walls.
• Lp(a) (Lipoprotein(a)): This particle resembles LDL but contains an additional protein called apolipoprotein(a). Higher levels of Lp(a) are already recognized as an established risk factor for coronary heart disease, and the new study confirms it shares many of the same inflammatory pathways as TRL.

Proteomics: A New Window Into Heart Disease

What sets this study apart is its methodology. Rather than simply measuring cholesterol levels, the researchers used proteomics analysis, the large-scale examination of proteins in the blood, to investigate how different lipoprotein particles actually affect the body at a molecular level.

The team analyzed measurements of nearly 3,000 proteins found in blood samples from approximately 35,269 UK Biobank participants who had no previous heart disease. They compared these protein patterns with genetic information and long-term health records spanning an average of 13.7 years. During that follow-up period, 1,599 participants developed coronary heart disease.

The researchers also validated their findings in a separate group of 5,915 participants from the US-based MESA study, strengthening the reliability of their conclusions.

The Inflammatory Connection

One of the most striking discoveries was the substantial overlap between TRL and Lp(a) in their associated protein patterns. Although these are biologically distinct particles, both appeared to activate similar inflammatory and vascular processes.

The researchers found that both TRL and Lp(a) carried proteins capable of attracting immune cells, potentially encouraging inflammation and changes in the structure of blood vessel walls. This suggests these particles contribute to cardiovascular disease not merely by depositing cholesterol, but by actively promoting inflammatory damage to arteries.

LDL showed a fundamentally different pattern. Its associated proteins were primarily connected to cholesterol accumulation, highlighting an important distinction in how each particle type contributes to heart disease.

The overlap for TRL and Lp(a) is one of the most interesting findings, Morze explained. It suggests that these particles may affect some of the same inflammatory and vascular processes. This could help identify targets for more precisely directed prevention in the future.

Quantifying the Hidden Risk

The study went beyond identifying biological mechanisms and attempted to quantify the actual risk these particles carry. Even after accounting for measured blood fat levels, a one standard deviation higher protein score for triglyceride-rich lipoproteins was associated with a 16 percent higher risk of coronary heart disease. For Lp(a), the corresponding figure was 9 percent higher risk.

Remarkably, approximately 62 percent of the risk associated with triglyceride-rich lipoproteins could be statistically explained by markers for immune activation and blood vessel remodeling. For Lp(a), that figure was 14 percent. No such association was found for the LDL protein pattern.

This suggests that a significant portion of the cardiovascular danger from TRL and Lp(a) operates through inflammatory pathways rather than through cholesterol deposition alone, which has profound implications for how we assess and treat heart disease risk.

Implications for Patient Care

The findings do not mean patients should abandon cholesterol-lowering medications. Lowering LDL cholesterol remains a cornerstone of prevention, emphasized Clemens Wittenbecher, who led the study and serves as Assistant Professor of Precision Medicine and Diagnostics at Chalmers. Our findings point to biological processes that may help explain some of the risk that remains beyond LDL. The next step is to establish whether measuring or targeting these processes can improve prevention alongside existing treatments.

However, the study does suggest that the current standard of care may be incomplete. Patients with normal LDL levels but elevated TRL or Lp(a) may be falsely reassured by their cholesterol test results. The research supports the growing call for more comprehensive lipid profiling that includes measurements of apolipoprotein B, which reflects the total count of all atherogenic particles, not just LDL cholesterol.

Limitations and Future Directions

The researchers acknowledge several important limitations. The study is observational, meaning it can identify associations but cannot definitively prove cause and effect. The UK Biobank participants are predominantly white (approximately 93 percent), which may limit the generalizability of findings to other populations. Blood samples were not collected in a fasting state, and the development and testing of protein patterns occurred largely within the same database.

Additionally, the study did not test a new treatment or establish a blood protein test ready for routine clinical use. Further research will be needed to determine whether measuring these inflammatory processes or developing treatments that specifically target them can meaningfully improve cardiovascular outcomes.

The Road Ahead for Heart Disease Prevention

Despite these limitations, the Chalmers study represents a significant step forward in understanding the complex biology of heart disease. By revealing that TRL and Lp(a) particles contribute to cardiovascular risk through shared inflammatory pathways, the research opens new possibilities for targeted therapies that go beyond cholesterol reduction.

The study also reinforces the importance of a comprehensive approach to heart health. While LDL cholesterol management remains essential, patients and physicians should be aware that other fat-carrying particles may pose significant risks through mechanisms that standard cholesterol tests do not capture.

As proteomics technology becomes more accessible and affordable, the day may come when a simple blood test can map thousands of proteins to provide a truly personalized cardiovascular risk profile. Until then, the message from this research is clear: bad cholesterol is only part of the story, and the hidden threats lurking beyond it deserve far more attention than they have received.

---

Edited by Palawan @QUE.COM
Website: https://QUE.COM Intelligence
Sponsored by: https://MAJ.COM AI Autonomous